Developing Potential Candidates of Preclinical Preeclampsia

International Journal of Molecular Sciences

Sandra Founds⁴  Xuemei Zeng²  David Lykins¹  James M. Roberts³ 

[1] Magee-Womens Research Institute, University of Pittsburgh, 204 Craft Avenue Pittsburgh, PA 15213, USA;Biomedical Mass Spectrometry Center Schools of the Health Sciences, University of Pittsburgh, Biomedical Science Tower 3, 3501 Fifth Avenue, Pittsburgh, PA 15261, USA;School of Medicine, Graduate School of Public Health and Magee-Womens Research Institute, University of Pittsburgh, 204 Craft Avenue Pittsburgh, PA 15213, USA;;School of Nursing and Magee-Womens Research Institute, University of Pittsburgh, 3500 Victoria St. 448 VB, Pittsburgh, PA 15261, USA

关键词: preeclampsia;    candidate gene;    candidate protein;    biomarker development;    prevention;   

DOI  :  10.3390/ijms161126023

来源: mdpi

【 摘 要 】

The potential for developing molecules of interest in preclinical preeclampsia from candidate genes that were discovered on gene expression microarray analysis has been challenged by limited access to additional first trimester trophoblast and decidual tissues. The question of whether these candidates encode secreted proteins that may be detected in maternal circulation early in pregnancy has been investigated using various proteomic methods. Pilot studies utilizing mass spectrometry based proteomic assays, along with enzyme linked immunosorbent assays (ELISAs), and Western immunoblotting in first trimester samples are reported. The novel targeted mass spectrometry methods led to robust multiple reaction monitoring assays. Despite detection of several candidates in early gestation, challenges persist. Future antibody-based studies may lead to a novel multiplex protein panel for screening or detection to prevent or mitigate preeclampsia.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.